{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:02:45Z","timestamp":1777489365361,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["G12 MD007597"],"award-info":[{"award-number":["G12 MD007597"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.abrep.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T22:15:56Z","timestamp":1494281756000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach"],"prefix":"10.1016","volume":"6","author":[{"given":"Earl B.","family":"Ettienne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edwin","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Maneno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adaku","family":"Ofoegbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverlyn","family":"Settles-Reaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Dunston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.abrep.2017.05.001_bb0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1360-0443.2011.03577.x","article-title":"A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine\/naloxone induction in heroin-dependent individuals","volume":"107","author":"Amass","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.abrep.2017.05.001_bb0010","author":"APA"},{"key":"10.1016\/j.abrep.2017.05.001_bb0015","series-title":"Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-phase Clinical Studies and Recommendations for Labeling","first-page":"1","author":"FDA","year":"2013"},{"issue":"10","key":"10.1016\/j.abrep.2017.05.001_bb0020","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.clinthera.2015.08.025","article-title":"Effects of a higher-bioavailability buprenorphine\/naloxone sublingual tablet versus buprenorphine\/naloxone film for the treatment of opioid dependence during induction and stabilization: A multicenter, randomized trial","volume":"37","author":"Gunderson","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.abrep.2017.05.001_bb0025","series-title":"Suboxone Prescribing Information","author":"Indivior","year":"2015"},{"key":"10.1016\/j.abrep.2017.05.001_bb0030","series-title":"Pharmacogenomics and Health Policy","author":"Issa","year":"2013"},{"key":"10.1016\/j.abrep.2017.05.001_bb0035","author":"Merriam-Webster Dictionary"},{"key":"10.1016\/j.abrep.2017.05.001_bb0040","author":"Merriam-Webster Dictionary"},{"key":"10.1016\/j.abrep.2017.05.001_bb0045","author":"Merriam-Webster Dictionary"},{"key":"10.1016\/j.abrep.2017.05.001_bb0050","author":"NIDA"},{"key":"10.1016\/j.abrep.2017.05.001_bb0055","author":"NIH"},{"key":"10.1016\/j.abrep.2017.05.001_bb0060","author":"NIH"},{"issue":"5","key":"10.1016\/j.abrep.2017.05.001_bb0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","article-title":"In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metabolism and Disposition"},{"issue":"1\u20132","key":"10.1016\/j.abrep.2017.05.001_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","article-title":"Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors","volume":"29","author":"Rendic","year":"1997","journal-title":"Drug Metabolism Reviews"},{"issue":"1","key":"10.1016\/j.abrep.2017.05.001_bb0075","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1124\/dmd.109.029546","article-title":"Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes","volume":"38","author":"Rouguieg","year":"2010","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.abrep.2017.05.001_bb0080","author":"SAMHSA"},{"key":"10.1016\/j.abrep.2017.05.001_bb0085","author":"SAMHSA"},{"key":"10.1016\/j.abrep.2017.05.001_bb0090","author":"Schuckit"},{"issue":"2","key":"10.1016\/j.abrep.2017.05.001_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpt.23","article-title":"Pharmacogenetics of opioid response","volume":"97","author":"Somogyi","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.abrep.2017.05.001_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.clpt.2005.11.015","article-title":"Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity","volume":"79","author":"Westlind-Johnsson","year":"2006","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.abrep.2017.05.001_bb0105","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.abrep.2017.05.001_bb0110","series-title":"Treatment of Opioid Dependence","author":"WHO","year":"2011"}],"container-title":["Addictive Behaviors Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853217300111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352853217300111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T21:57:40Z","timestamp":1535839060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352853217300111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":22,"alternative-id":["S2352853217300111"],"URL":"https:\/\/doi.org\/10.1016\/j.abrep.2017.05.001","relation":{},"ISSN":["2352-8532"],"issn-type":[{"value":"2352-8532","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abrep.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}